CRITERIA FOR EVALUATING PATIENTS UNDERGOING CHEMOTHERAPY FOR MALIGNANT BRAIN TUMORS

CRITERIA FOR EVALUATING PATIENTS UNDERGOING CHEMOTHERAPY FOR MALIGNANT BRAIN TUMORS
复制标题

DOI:
10.3171/jns.1977.47.3.0329
复制
发表时间:
1977-01-01
影响因子:
4.1
通讯作者:
WILSON, CB
WILSON, CB
中科院分区:
医学1区
文献类型:
--
作者:
LEVIN, VA;CRAFTS, DC;WILSON, CB

文献摘要

被引文献

相似文献

评价脑肿瘤患者的评价标准,并设计了一个数字评分量表来指定对测试的反应。在100例患者的经验中讨论了允许准确预测治疗期间反应或恶化的测试组合的可靠性。本文总结了神经系统检查、放射性核素脑扫描、计算机断层扫描(CT)和脑电图在脑肿瘤化疗和放化疗中判断疗效(肿瘤消退)或恶化(肿瘤生长)的预测价值。通过回顾性分析,神经系统检查、放射性核素扫描和CT扫描作为预测治疗反应的检查具有同等价值。在预测治疗期间恶化方面,神经系统检查或放射性核素骨显像的预后价值中等上级于CT扫描。在神经系统检查、放射性核素骨扫描和CT扫描在同一测试期间进行,并仔细监测类固醇剂量的情况下,3项测试中的2项准确预测了65%患者的恶化,82%的患者对治疗有反应。当2个正相关的测试发生在平均7周内时,3个测试中的2个正确地确定了剩余35%的患者的恶化,以及剩余18%的患者的反应。
Criteria for evaluating brain tumor patients were evaluated, and a numerical rating scale was devised to designate response to testing. The reliability of test combinations that permit accurate prediction of response or deterioration during therapy was discussed in experience with 100 patients. The paper summarizes the predictive value of the neurological examination, radionuclide scintiscan computerized tomographic brain scan (CT scan) and EEG, in the determination of response (tumor regression) or deterioration (tumor growth) during brain tumor chemotherapy and chemotherapy-radiotherapy. By retrospective analysis, the neurological examination, radionuclide scintiscan and CT scan were of equal value individually as tests to predict response to therapy. The prognostic values of the neurological examination or radionuclide scintiscan were moderately superior to the CT scan in predicting deterioration during therapy. Under circumstances whereby a neurological examination, radionuclide scintiscan and CT scan were performed during the same testing session, and steroid dosage was carefully monitored, 2 of the 3 tests accurately predicted deterioration in 65% of patients, and response to therapy in 82% of patients. Two of the 3 tests correctly established deterioration in the remaining 35% of patients, and response in the remaining 18% of patients, when the 2 positively correlated tests occurred within a mean period of 7 wk.